

WHO Drug Information

Volume 20, 2006 : Index

A

Abetimus, request withdrawn, (4) 273
 Access to medicines, developing countries, (3) 191
 ACE inhibitors, birth defects, (2) 70
 pregnancy, (2) 71
 Acetylsalicylic acid, ibuprofen, (3) 188
 Adherence to Model List of Essential Medicines,
 2-country study, (2) 78
 Adverse reaction reporting, (4) 276
 Adverse reactions, children, (3) 183
 online reporting, (4) 249
 African scientists join forces, (4) 266
 Analgesic ladder, WHO, (2) 105
 Antibiotic use, (1) 31
 Antiretroviral price list, (3) 200
 programmes, (1) 30
 treatment failure, (3) 200
 Antisera supply, (1) 5
 Antithrombin alfa, transgenic, (2) 86
 Aprotinin, renal toxicity, (1) 16
 Artesunate, fake, (3) 193
 International Pharmacopoeia monograph, (2) 106
 tablets, International Pharmacopoeia monograph,
 (2) 107
 Article 58, initiative, (1) 19
 Asthma/COPD drugs PDD/DDD, (4) 261
 ATC synthase inhibitor, (4) 243
 ATC/DDD list, final , February 2006, (2) 97
 temporary, March 2006, (2) 97
 Atomoxetine, suicidality, (1) 9
 Avian influenza, WHO guidelines, (2) 104

B

Benzocaine spray, methaemoglobinaemia, (1) 16
 Bevacizumab, lung cancer, (4) 271
 Bioglue®, inflammation, (4) 250
 Biological standardization, (1) 6
 Biologicals regulation, world health, (3) 173
 Biosimilar product approved, (1) 27
 Biphosphonates, osteonecrosis, (3) 181
 Boletín farmacos, (1) 30
 Bupropion, seasonal depression, (2) 86

C

Calcitriol, safety, (3) 186
 Capecitabine & warfarin, interaction (1) 9
 Case safety reports, (1) 26
 Cetuximab, cancer, (1) 28

Ciclosporine, safety, (3) 186
 Cisplatin, & topotecan cancer, (2) 87
 Clarithromycin, safety, (3) 186
 Clinical trial registry, WHO, (1) 35
 Clopidogrel, (3) 199
 Clozapine, monitoring, (1) 10
 Colchicine, dosage, (4) 252
 toxicity, (1) 17
 Compulsory licensing, regulation, (2) 90
 Contraception, emergency, (3) 197
 Contraceptive skin patch, (2) 69
 Corticosteroids, topical, (1) 18
 Counterfeit, guidance, pharmacists, (2) 104
 medicines, (1) 3
 taskforce, WHO, (3) 192
 taskforce strategy, (4) 268
 Counterfeiting resolution, (3) 193

D

Darifenacin, advantage?, (4) 258
 Daunorubicin, safety, (3) 186
 Decitabine, myelodysplastic syndromes, (2) 87
 Declaration of Rome, counterfeit, (1) 4
 Defined and prescribed daily doses, pharmaco-
 epidemiology, (4) 261
 Development, new TB drugs, (4) 240
 Diarylquinolone, (4) 242
 Diethylene glycol, Panama, (4) 248
 Dipiperidine, (4) 243
 Dolasetron, cardiovascular reactions, (3) 185
 Dronedaron, withdrawal (3) 199
 Drug dependence, Expert Committee recommenda-
 tions, (3) 190
 Drug-resistant tuberculosis, (4) 239

E

EMA management board, (2) 86
 Emergency health kit, (2) 103
 Enoxaparin, kidney disease, (3) 182
 Epilepsy drugs, teratogenicity, (4) 246
 Ergot derivatives, fibrotic reactions, (1) 15
 Essential medicines, children, (3) 191
 paediatric, (4) 266
 Extensively drug-resistant tuberculosis, (4) 239
 Ezetimibe, depression (4) 256

F

Flucitasone, safety, (3) 186
 Fluoroquinolones, tendon disorders, (1) 15
 Fluoroquinolones, warfarin, (1) 9
 Fluoxetine, children, (2) 89
 safety, (3) 187

G

Gadolinium contrast agents, fibrosis, (2) 71
 Galantamine, fatal outcome, (1) 14
 Gatifloxacin, blood glucose disturbances, (2) 72
 tuberculosis, (1) 11
 Global Task Force on XDR-TB, (4) 239
 Guidance documents, USA, (4) 280

H

Hepatitis A vaccine, paediatric, (1) 26
 HPV vaccine, (2) 88
 Hydroxyurea, cutaneous toxicities, (1) 17

I

Ibuprofen, acetylsalicylic acid, (3) 188
 ICDRA, International Conference of Drug Regulatory
 Authorities, (2) 61
 ICH, processes, (4) 267
 Innovation & intellectual property, (4) 277
 Imatinib, cardiac dysfunction, (4) 248
 revised indications, (4) 273
 Immune globulin, immune deficiency, (1) 27
 haemolysis, (1) 16
 Immunization adverse events, monitoring, (3) 180
 Immunomodulators, carcinogenic?, (1) 13
 IMPACT, counterfeit, (1) 3
 Independent drug bulletins, (1) 29
 Infectivity, TSE, (2) 91
 Infliximab, lymphoma, (3) 181
 Influenza virus vaccine, 2006, Northern hemisphere,
 (3) 196
 2007, Southern hemisphere, (4) 272
 InhA inhibitors, (4) 244
 Initiative to evaluate developing country medicines,
 (1) 19
 Innovation, intellectual property rights, public
 health (3) 202
 Intellectual property rights, innovation, public
 health (3) 202
 Intellectual property, public hearings, innovation, (4) 277
 International Conference of Drug Regulatory
 Authorities, ICDRA, (2) 61
 International nonproprietary names (INN),
 proposed list, 95, (2) 115
 proposed list, 96, (4) 281
 recommended list, 55, (1) 37
 recommended list, 56, (3) 203
 Inventory software, (4) 276
 Isocitrate lyase inhibitors, (4) 244

K

Ketamine, classified, (1) 28

L

Lamivudine & zidovudine, International Pharmacopoeia
 monograph, (2) 112
 Lamivudine, oral solution, International Pharmacopoeia
 monograph, (2) 107
 tablets, International Pharmacopoeia monograph,
 (2) 109
 Lamotrigine, oral cleft, (3) 181
 Leflunomide, neuropathy, (4) 256
 Lidocaine/prilocaine, safety, (3) 186
 Lothian Formulary, Model List of Essential Medicines,
 study, (2) 73

M

Malaria, WHO treatment recommendations, (1) 33
 Medical device innovation, (2) 87
 Meningococcal vaccine, Guillain Barré, (4) 247
 Model List of Essential Medicines, adherence,
 2-country study, (2) 78
 Model List of Essential Medicines, formulary, study,
 (2) 73
 Monoclonal antibodies, (3) 165

N

Nanotechnology-based products, (3) 200
 Natalizumab, (2) 90
 Neonate medicines development, (4) 265
 Nimesulide, safety, (3) 187
 Nitrofurantoin, lung function, (4) 252
 Nitroimidazole, (4) 242-3
 NSAIDS, tenofovir, renal failure, (2) 69

O

Oseltamivir, safety update, (4) 257
 safety, (1) 11

P

Paediatric, essential medicines, (4) 266
 drug information, (1) 31
 formulations, resources, (2) 105
 Paroxetine, teratogenicity, (1) 12
 Patient health & safety, (1) 29
 Pegaptanib, hypersensitivity, (1) 16
 Pharmaceutical Forum, (4) 278
 Pharmaceutical policy analysis, (4) 279
 Pharmacoepidemiology, prescribed and defined daily
 doses, (4) 261
 Pharmacovigilance, Vigiflow online, (4) 275
 Pharmacy education, (4) 278
 Pipeline, TB drugs, (4) 241
 Plant names, (4) 275
 Pleuromutilins, (4) 243

Prequalified products, (3) 198
 Prescribed and defined daily doses in
 pharmacoepidemiology, (4) 261
 Prescribing information requirements, (1) 26
 Procurement, good governance, (4) 276
 Promethazine, children, (1) 12
 Propafenone, safety, (3) 187
 Proton pump inhibitors, interstitial nephritis, (4) 253
 testosterone, (1) 17
 Public hearings innovation & intellectual property,
 (4) 277
 Pyrrole, (4) 243

Q

Quality assurance, guidance, (1) 34
 Quality systems, guidance, (4) 279
 Quetiapine, urinary disorders, (1) 17

R

Rasagiline, Parkinson disease, (2) 88
 Rational medicines management, (1) 31
 Rational use of drugs, network, (1) 31
 Regulatory pathways, European Union, (1) 19
 ReNu Moistureloc® withdrawal, (3) 197
 Repaglidine, request withdrawn, (4) 273
 Rheumatology guidelines, (2) 103
 Risperidone, autism, (4) 271
 Ritonavir, safety, (3) 187
 Rosiglitazone, diabetic macular oedema, (1) 12

S

Saquinavir, withdrawal, (3) 197
 Selegiline, depression (1) 28
 Specifications for pharmaceutical preparations, (2) 103
 Sirolimus, rejection, (4) 257
 Sitagliptin, diabetes, (4) 272
 SSRI, newborns, lung disorder, (2) 70
 tricyclic antidepressants, interaction, (4) 249
 Surfaxin withdrawal, (2) 89

T

TB drug development, (4) 240
 Telbivudine, hepatitis B, (4) 271

Telithromycin, hepatic events, (4) 250
 Telithromycin, liver toxicity, (1) 14
 Tenecteplase, withdrawal, (1) 27
 Tenofovir, NSAIDS, renal failure, (2) 69
 Terbenafine, blood dyscrasias, (3) 183
 Tigecycline, infections, (4) 258
 Tipranavir, intracranial haemorrhage, (3) 180
 TNF alfa products, hepatitis B, (1) 10
 TNF alfa, hepatitis B, (3) 185
 Topotecan & cisplatin, cancer, (2) 87
 Translocase I inhibitor, (4) 243
 Trastuzumab, breast cancer, (1) 196
 Treatment, malaria, WHO recommendations, (1) 33
 Tricyclic antidepressants, SSRI, interaction, (4) 249
 Triple whammy, (4) 251
 Tropical disease strategy, (4) 267
 TSE, infectivity, (2) 91

U

Unapproved marketed drugs, guide, (2) 104

V

Vaccine, hepatitis A, paediatric, (1) 26
 HPV, (2) 88
 influenza virus, 2006 Northern hemisphere, (3) 196
 influenza virus, 2007 Southern hemisphere, (4) 272
 meningococcal, Guillain Barré, (4) 247
 Valproic acid, pancreatitis, (3) 185
 vCJD infectivity, TSE, (2) 91
 Verapamil, safety, (3) 187
 Vigiflow online, pharmacovigilance, (4) 275
 Vinorelbine, safety, (3) 187

W

Warfarin, capecitabine, interaction (1) 9
 Warfarin, fluoroquinolones, (1) 9

Z

Zidovudine & lamivudine, International Pharmacopoeia
 monograph, (2) 112